Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NYSE: EW

Edwards Lifesciences Corporation

Healthcare | Medical - Devices
$89.90 +0.12 (+0.13%) as of 2026-09-05 12:07 UTC
Market Cap$51.8B
Volume2.62M
EPS (TTM)$1.83

Edwards Lifesciences Corporation (NYSE: EW) is a $51.8B medical - devices company trading at $89.90 (+0.1% today) — 49.1× trailing earnings. Figures from SEC EDGAR and market feeds; updated 2026-09-05 12:07 UTC.

52-Week Range
Low $76.49High $96.29

What Edwards Lifesciences Corporation does

Edwards Lifesciences is a structural heart company that develops medical technologies to treat advanced cardiovascular disease, with a focus on therapies for heart valve disorders and heart failure. The company offers three main product groups: transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, and surgical structural heart products. Its offerings include both catheter-based minimally invasive procedures that do not require open-heart surgery and traditional surgical approaches using bioprosthetic valves and repair devices.

Summarized from Edwards Lifesciences Corporation’s SEC filings · Read the filing ↗

Key facts

Quote
Price$89.90
Change (1D)+0.12 (+0.13%)
Market cap$51.8B
Volume2.62M shares
52-week range$76.49 – $96.29
Valuation
P/E (TTM)49.13×
EV/EBITDA34.80×
EPS (TTM)$1.83
Price/book5.01×
Return on equity10.38%
Debt/equity0.06
Returns
52-week return+17.5%

Revenue, margins & earnings

FY2021 Net income: $1.50BFY2021 Taxes & interest: $187MFY2021 Operating expenses: $2.29BFY2021 Cost of revenue: $1.25B$5.23BFY2021FY2022 Revenue: $4.46B — margin split not shown (non-operating gains)$4.46BFY2022FY2023 Revenue: $5.01B — margin split not shown (non-operating gains)$5.01BFY2023FY2024 Revenue: $5.44B — margin split not shown (non-operating gains)$5.44BFY2024FY2025 Net income: $1.07BFY2025 Taxes & interest: $191MFY2025 Operating expenses: $3.47BFY2025 Cost of revenue: $1.33B$6.07BFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
Annual revenue; bands show net, operating, gross margins · Open in Platform →
Net income for FY2021, FY2022 is the filer’s available-to-common figure (net of preferred dividends) — the filer tags no parent net income for those years.

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-08-31
  • 2026-08-31Dahl Andrew M.SVP, Corporate ControllerSELL-544$49.5K
  • 2026-08-28Bruls AnnetteCVP, EMEACLASELL-2,644$237.9K
  • 2026-08-26Chopra DaveenCVP, TMTT, Surgical & IHFMSELL-1,154$105.9K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Edwards Lifesciences Corporation do?

Edwards Lifesciences is a structural heart company that develops medical technologies to treat advanced cardiovascular disease, with a focus on therapies for heart valve disorders and heart failure.

What is EW's valuation?

EW trades at $89.90, 49.13× trailing earnings, 34.80× EV/EBITDA, as of 2026-09-05.

When did EW last file with the SEC?

Edwards Lifesciences Corporation's most recent SEC filing on record is a 8-K filed 2026-05-08. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-09-05 12:07 UTC. This page is also available as JSON at /api/data?ticker=EW and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for EW and 5,000+ tickers.

Create a free account — keep EW
For your agent
GET /api/data?ticker=EW

This page as JSON via rel="alternate" · REST API docs · MCP server (59 tools) · llms.txt